Quality of life after immune suppressive therapy in aplastic anemia
Acquired aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells,
Aplastic Anemia
Yasmin Abaza, MD
Institution
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Neal Young, MD
Institution
National Heart, Lung, and Blood Institute - National Institutes of Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Neal Young received a A.B. cum laude from Harvard College in 1967 and his M.D. in 1971 from the Johns Hopkins School of Medicine. He did post-graduate medical training at Massachusetts General Hospital and Barnes Hospital at Washington University in St. Louis before joining the NHLBI in 1981. He is a Master of the American College of Physicians and has accrued many academic honors. His efforts as a US Government employee were recognized with Samuel J. Heyman Service to America Medal in Science and the Environment. Dr. Young has authored over 280 original scientific and medical articles in peer
Zhuoer Xie, MD, MS
Institution
Moffitt Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Xie is a hematologist and assistant member in the Moffitt Cancer Center Malignant Hematology Department. Dr. Xie completed her hematology/oncology fellowship training at the Mayo Clinic, Rochester, MN, Master of Science in Clinical Research and Geriatric fellowship training at the UCLA, Ronald Reagan Medical Center. She focuses on treating myeloid malignancies and precursor stages, including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia (CCUS), MDS, MPN, CMML, and Acute Leukemia. Her research focuses on clinical and translational science, including identifying
Jill de Jong, MD, PhD
Institution
University of Chicago Medicine, Comer Children's Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
Kohei Hosokawa, MD, PhD
Institution
Kanazawa University Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pedro Prata, MD, PhD
Institution
Centre Hospitalier Universitaire à Limoges
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease
Original Publication Date
Article Source
External Web Content
Abstract Over the past 10 years, there has been a marked increase in recognition of the interplay between the intestinal microbiome and the hematopoietic system. Despite their apparent distance in the body, a large literature now supports the relevance of the normal intestinal…
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
Original Publication Date
Article Source
External Web Content
Key Points SCT from MUD offers superior survival outcomes for severe aplastic anemia compared to both MMUD and Haplo. The decision between a MMUD or Haplo donor in the absence of an available MUD remains uncertain. Selecting the most suitable alternative donor becomes challenging…
Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities
Original Publication Date
Article Source
External Web Content
Key Points The number of autoHCT and alloHCT grew faster in Non-Hispanic African Americans and Hispanics compared to Non-Hispanic Whites. Survival after autoHCT and alloHCT improved over time for all racial/ ethnic groups, though African Americans have worse outcomes. There has…